Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

genentech, inc. - alteplase (unii: 1rxs4ue564) (alteplase - unii:1rxs4ue564) - alteplase 50 mg in 50 ml - activase is indicated for the treatment of acute ischemic stroke. exclude intracranial hemorrhage as the primary cause of stroke signs and symptoms prior to initiation of treatment [see contraindications (4.1)] . initiate treatment as soon as possible but within 3 hours after symptom onset. activase is indicated for use in acute myocardial infarction (ami) for the reduction of mortality and reduction of the incidence of heart failure. limitation of use: the risk of stroke may outweigh the benefit produced by thrombolytic therapy in patients whose ami puts them at low risk for death or heart failure. activase is indicated for the lysis of acute massive pulmonary embolism, defined as: - acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments. - acute pulmonary emboli accompanied by unstable hemodynamics, e.g., failure to maintain blood pressure without supportive measures. do not administer activase to treat acute ischemic stroke in the following situations in which the risk of bleedi

Malta - engleză - Medicines Authority

boehringer ingelheim international gmbh binger strasse 173, 55216 ingelheim am rhein, germany - alteplase - powder and solvent for solution for infusion or injection - alteplase 50 mg - antithrombotic agents

Malta - engleză - Medicines Authority

boehringer ingelheim international gmbh binger strasse 173, 55216 ingelheim am rhein, germany - alteplase - powder and solvent for solution for infusion or injection - alteplase 20 mg - antithrombotic agents

Malta - engleză - Medicines Authority

boehringer ingelheim limited - alteplase - powder and solvent for solution for infusion or injection - alteplase 50 mg - antithrombotic agents

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - alteplase - powder and solvent for solution for injection/infusion - 2 milligram(s) - alteplase

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

boehringer ingelheim limited - alteplase - powder and solvent for solution for injection/infusion - 20 milligram(s) - enzymes; alteplase

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

boehringer ingelheim limited - alteplase - powder and solvent for solution for injection/infusion - 50 milligram(s) - enzymes; alteplase

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - alteplase 20mg - injection with diluent - 20 mg - active: alteplase 20mg excipient: arginine nitrogen phosphoric acid polysorbate 80 water for injection - actilyse is indicated for fibrinolytic therapy in acute thrombotic artery occlusion to restore coronary artery patency, reduce infarct size, preserve ventricular function, prevent cardiac insufficiency and reduce mortality · 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h of symptom onset; · 3 hour dose regimen: for patients in whom treatment can be started between 6 - 12 hrs after symptom onset.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - alteplase 50mg - injection with diluent - 50 mg - active: alteplase 50mg excipient: arginine nitrogen phosphoric acid polysorbate 80 water for injection - actilyse is indicated for fibrinolytic therapy in acute thrombotic artery occlusion to restore coronary artery patency, reduce infarct size, preserve ventricular function, prevent cardiac insufficiency and reduce mortality · 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h of symptom onset; · 3 hour dose regimen: for patients in whom treatment can be started between 6 - 12 hrs after symptom onset.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - alteplase, quantity: 2 mg - injection, powder for - excipient ingredients: phosphoric acid; polysorbate 80; arginine; nitrogen - actilyse cathflo is indicated for the thrombolytic treatment of occluded central venous access devices including those used for haemodialysis. the 2 mg strength of alteplase (actilyse cathflo) is the only recommended presentation for use in this indication. see also precautions - use in children.